Maria Rosaria Valerio

Dr. Maria Rosaria Valerio


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
DSDaniela Sambataro
Daniela Sambataro
GSGiuseppa Scandurra
Giuseppa Scandurra
LSLinda Scarpello
Linda Scarpello
Vittorio GebbiaVittorio Gebbia
Vittorio Gebbia
Ligia DominguezLigia Dominguez
Ligia Dominguez
MVMaria Rosaria Valerio
Maria Rosaria Valerio
Magnesium (Mg2+) has gained oncologists’ attention due to its wide range of biological functions and frequent use as a complementary or integrative agent. This review outlines Mg’s actions, its complex role in carcinogenesis and tumor risk, and clinical issues. Mg2+ is essential in numerous biochemical processes, including adenosine triphosphate production, cellular signal transduction, DNA, RNA and protein synthesis, and bone formation. Pertinent full-text articles were thoroughly examined, and the most relevant ones were selected for inclusion in this review. There is conflicting scientific evidence about the relationship between Mg2+ changes and cancer risk, apart from colorectal cancer. Chronic Mg2+ deficiency leads to immune dysfunctions and enhanced baseline inflammation associated with oxidative stress related to various age-associated morbidities and cancer. On the other hand, Mg2+ deficiency is associated with drug or chemotherapy-related hypomagnesemia, postoperative pain, cachexia, opioid-induced constipation, normal tissue protection from radiation damage, and prevention of nephrotoxicity. A balanced diet usually provides sufficient Mg2+, but supplementation may be necessary in some clinical settings.

5 July 2024 in Cancers
Verified
Journal Article
Open access
PDF file
GSGiuseppa Scandurra
Giuseppa Scandurra
Valentina N. LombardoValentina N. Lombardo
Valentina N. Lombardo
GSGiuseppe Scibilia
Giuseppe Scibilia
DSDaniela Sambataro
Daniela Sambataro
Vittorio GebbiaVittorio Gebbia
Vittorio Gebbia
MVMaria Rosaria Valerio
Maria Rosaria Valerio
Brain metastases (BM) pose a significant challenge in the management of HER2+ breast cancer since almost 50% of patients with HER2+ breast cancer develop brain tumors. The complex process of brain metastases involves genetic mutations, adaptations and mechanisms to overcome the blood–brain barrier. While radiotherapy is still fundamental in local therapy, its use is associated with cognitive adverse effects and limited long-term control, necessitating the exploration of alternative treatments. Targeted therapies, including tyrosine kinase inhibitors, monoclonal antibodies, and antibody–drug conjugates, offer promising options for HER2+ breast cancer patients with BM. Clinical trials have demonstrated the efficacy of these agents in controlling tumor growth and improving patient outcomes, posing the question of whether radiotherapy is always the unique choice in treating this cancer. Ongoing research into novel anti-HER2 antibodies and innovative combination therapies holds promise for advancing treatment outcomes and enhancing patient care in this clinical scenario. This narrative review provides a comprehensive overview of traditional medical treatments, molecularly targeted therapy and investigational agents in the management of HER2+ breast cancer with BM, highlighting the evolving landscape and potential future directions in treatment strategies to improve patient survival and quality of life.

12 May 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
DSDaniela Sambataro
Daniela Sambataro
GSGiuseppa Scandurra
Giuseppa Scandurra
LSLinda Scarpello
Linda Scarpello
Vittorio GebbiaVittorio Gebbia
Vittorio Gebbia
Ligia DominguezLigia Dominguez
Ligia Dominguez
MVMaria Rosaria Valerio
Maria Rosaria Valerio
Magnesium (Mg2+) has gained oncologists’ attention due to its wide range of biological functions and frequent use as a complementary or integrative agent. This review outlines Mg's actions, its complex role in carcinogenesis and tumor risk, and clinical issues. Mg2+ is essential in numerous biochemical processes, including adenosine triphosphate production, cellular signal transduction, DNA, RNA and protein synthesis, and bone formation. The authors conducted a literature review on MEDLINE, PubMed, EMBASE, and the Web of Science to report the relationship between Mg2+ and cancer. Pertinent full-text articles were thoroughly examined, and the most relevant ones were selected for inclusion in this review. Mg2+ alterations are associated with cancer risk variably since scientific evidence is not univocal, except for colorectal cancer. Chronic Mg2+ deficiency leads to immune dysfunctions and enhanced baseline inflammation associated with oxidative stress related to various age-associated morbidities and cancer. On the other hand, Mg2+ deficiency is associated with several clinical settings, such as drug or chemotherapy-related hypomagnesemia, postoperative pain, cachexia, opioid-induced constipation, normal tissue protection from radiation damage, and prevention of nephrotoxicity. The issue of Mg2+ supplementation is also analyzed. A balanced diet usually provides sufficient Mg2+, but supplementation may be necessary in some clinical settings. Excessive supplementation can negatively impact immune function and should be avoided.

21 February 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
MVMaria Rosaria Valerio
Maria Rosaria Valerio
FMFederica Martorana
Federica Martorana
Maria Vita SanòMaria Vita Sanò
Maria Vita Sanò
DSDaniela Sambataro
Daniela Sambataro
GMGianmarco Motta
Gianmarco Motta
GSGiuseppa Scandurra
Giuseppa Scandurra
Background: Adherence to oral anticancer therapies among breast cancer patients is an often-overlooked issue. A lack of patient compliance can be caused by several factors, and may hinder the efficacy of prescribed medication, leading to a shorter than expected survival. In this context, few data about adherence to CDK4/6 inhibitors in real-world practice are available. We report here the results of a retrospective analysis of adherence to abemaciclib plus endocrine therapy in a cohort of women with hormone receptor-positive (HR+), epidermal growth factor 2 negative (HER2−) breast cancer. Methods: Abemaciclib adherence was computed as the ratio between the total number of cycles/months that medication was supplied and the months between the first and the last prescription. The proportion of Days Covered (PDC) ranged from 0 to 1. A score of 0.8 (i.e., 80% adherence rate) was the cutoff used to classify the patients as adherent (0.8 ≤ PDC ≤ 1) or non-adherent (0 ≤ PDC < 0.8). The received dose intensity was also calculated. Results: The abemaciclib pharmacy claims of 100 women with HR+/HER2− breast cancer were retrieved. Most patients (91%) were treated in the advanced setting. Abemaciclib was more frequently taken with an aromatase inhibitor (63%) than with fulvestrant (27%). In this population, the adherence rate was high (92.25% + 1.939 SD). The proportion of non-adherent patients taking abemaciclib with PDC <0.8 was 12%. There was a significative correlation between the occurrence of side effects and the use of <5 drugs for non-oncological illnesses, probably reflecting concomitant non-oncological diseases. Conclusions: Adherence to abemaciclib-based therapy is high in a real-life setting, pending the adequate and proactive management of patients. The careful evaluation of patients and detailed information about expected adverse events are essential to ensure adherence to this antineoplastic agent.

30 September 2024 in Cancers
Verified
Journal Article
Open access
PDF file
CCCalogero Cipolla
Calogero Cipolla
Vittorio GebbiaVittorio Gebbia
Vittorio Gebbia
EDEleonora D'Agati
Eleonora D'Agati
MGMartina Greco
Martina Greco
CMChiara Mesi
Chiara Mesi
MVMaria Rosaria Valerio
Maria Rosaria Valerio
Background. In breast cancer (BC) patients, axillary management has undergone major improvements over the last few years, and efforts to identify the optimal strategy for the management of axillary surgery are still ongoing. Methods. In current clinical practice, women with clinically node-positive (cN+) BC usually receive neoadjuvant chemotherapy (NACT) with the aim of reducing the extent of primary disease and, thus, allowing for axillary-conservative surgery. Remarkably, after NACT, up to one out of three patients achieves an axillary pathologic complete response, which, in turn, is associated with a more favorable prognosis than residual axillary disease. However, NACT is not without drawbacks, as NACT-associated inflammation can damage lymphatic vessels. Furthermore, varying degrees of response may occur in the axillary lymph nodes, increasing the false negative rate for sentinel biopsy. Results. At present, there is no consensus on the optimal approach in patients with cN+ BC undergoing NACT, although multidisciplinary management seems to be recommended. Conclusions. This narrative review provides a comprehensive overview of axillary management in cN+ BC patients undergoing NACT. It uses a multidisciplinary approach that encompasses the oncological management perspectives, as well as surgical and chemotherapeutic viewpoints.

22 March 2025 in Cancers
Verified
Journal Article
Open access
PDF file
DSDaniela Sambataro
Daniela Sambataro
SBSandro Bellavia
Sandro Bellavia
PMPaolo Di Mattia
Paolo Di Mattia
DCDanilo Centonze
Danilo Centonze
CECarmela Emmanuele
Carmela Emmanuele
MVMaria Rosaria Valerio
Maria Rosaria Valerio
Background: Mixed neuroendocrine–non-neuroendocrine tumors (MINEN) of the liver are exceptionally rare, with limited data available regarding their clinical behavior, pathogenesis, and optimal management. The coexistence of hepatocellular carcinoma (HCC) and neuroendocrine carcinoma (NEC) within the liver presents diagnostic and therapeutic challenges. Methods: A systematic literature search was conducted on PubMed, identifying cases of primary mixed HCC and NEC in the liver. The search adhered to PRISMA guidelines, and relevant studies were critically analyzed. A total of 45 documented cases were reviewed, focusing on patient demographics, clinical characteristics, treatment strategies, and outcomes. Results: Most patients (90%) were male, with a median age of 66.5 years. Hepatitis B or C infection was present in 74% of cases, and liver cirrhosis was reported in 38%. The combined type was the most frequently observed histological pattern (65%). Treatment modalities varied, including transarterial chemoembolization (TACE), radiofrequency ablation (RFA), surgery, and systemic therapies. The median overall survival was 10 months, highlighting the aggressive nature of these tumors. Conclusions: Given the rarity and poor prognosis of hepatic MINEN tumors, multidisciplinary management is essential. Advanced molecular profiling may offer insights into tumor biology and potential therapeutic targets. Future research should explore novel systemic therapies, including immune checkpoint inhibitors, to improve patient outcomes.